OBJECTIVE： To observe the efficacy and safety of benazepril combined with dobesilate calcium assisted with insulin in the treatment of elderly patients with early diabetic nephropathy. METHODS： 200 elderly patients with early diabetic nephropathy were randomly divided into control group （100 cases） and observation group （100 cases）. All patients received insulin pump continuous subcutaneous injection of Recombinant human insulin injection 0.4-0.6 unit/（kg·d）before going to bed， pumped the total amount of 50％， the other amount was equally distributed before the meals， ensuring fasting blood glucose 4.4-6.1 mmol/L and 2 h postprandial blood glucose 4.4-8.0 mmol/L. Based on it， control group was orally given Benazepril hydrochloride tablet 10 mg， once a day； observation group was additionally given Dobesilate calcium granule 0.5 g， orally， 3 times a day. 2 groups were treated for 8 weeks. Clinical efficacy， renal function， cystatin （Cys） -C， high sensitivity C-reactive protein （hs-CRP）， QLQ-C30 score before and after treatment， and the incidence of adverse reactions in 2 groups were observed. RESULTS： The total effective rate in observation group was significantly higher than control group， with statistical significance （P＜0.05）. After treatment， the renal function indexes， Cys-C and hs-CRP level in 2 groups were significantly better than before， and observation group was better than control group；QOL-C30 score was significantly higher than before， and observation group was higher than control group， with statistical significances （P＜0.05）. And there was no significant difference in the incidence of adverse reactions（P＞0.05）. CONCLUSIONS： Benazepril combined with dobesilate calcium assisted with insulin show obvious efficacy in the treatment of elderly patients with early diabetic nephropathy， which can effectively improve clinical symptoms， promote renal function recovery， improve the quality of life， and do not increase the incidence of adverse reactions.